Log in or register to see all Alerts
New HTA Decisions in England
June 2020
Drug name
LUCENTIS® (ranibizumab)
Company
Novartis
Decision date
30/06/2020
Therapeutic area
Diabetes and other endocrinal, nutritional and metabolic conditions
Therapeutic sub area
Endocrinal, nutritional and metabolic conditions: general and other
Decision
Recommended
Indication
Diabetic retinopathy.
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation about the use in the NHS of ranibizumab (Lucentis) for treating diabetic retinopathy because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.